Eton Pharmaceuticals Inc [ETON] stock is trading at $15.8, up 9.80%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The ETON shares have gain 10.88% over the last week, with a monthly amount drifted -8.41%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Eton Pharmaceuticals Inc [NASDAQ: ETON] stock has seen the most recent analyst activity on January 23, 2025, when H.C. Wainwright reiterated its Buy rating and also boosted its price target to $33 from $17. Previously, B. Riley Securities started tracking the stock with Buy rating on January 10, 2025, and set its price target to $21. On January 06, 2025, H.C. Wainwright reiterated its Buy rating and revised its price target to $17 on the stock. Craig Hallum initiated its recommendation with a Buy and recommended $8 as its price target on May 06, 2024. In a note dated January 04, 2021, H.C. Wainwright reiterated an Buy rating on this stock and revised its target price from $20 to $15.
Eton Pharmaceuticals Inc [ETON] stock has fluctuated between $3.25 and $21.48 over the past year. Currently, Wall Street analysts expect the stock to reach $35 within the next 12 months. Eton Pharmaceuticals Inc [NASDAQ: ETON] shares were valued at $15.8 at the most recent close of the market. An investor can expect a potential return of 121.52% based on the average ETON price forecast.
Analyzing the ETON fundamentals
Eton Pharmaceuticals Inc [NASDAQ:ETON] reported sales of 48.33M for the trailing twelve months, which represents a growth of 116.95%. Gross Profit Margin for this corporation currently stands at 0.58% with Operating Profit Margin at -0.05%, Pretax Profit Margin comes in at -0.09%, and Net Profit Margin reading is -0.09%. To continue investigating profitability, this company’s Return on Assets is posted at -0.05, Equity is -0.23 and Total Capital is -0.04. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 14.88 points at the first support level, and at 13.96 for the second support level. However, for the 1st resistance point, the stock is sitting at 16.32, and for the 2nd resistance point, it is at 16.83.
Ratios To Look Out For
For context, Eton Pharmaceuticals Inc’s Current Ratio is 1.97. As well, the Quick Ratio is 1.43, while the Cash Ratio is 0.69. Considering the valuation of this stock, the price to sales ratio is 8.77, the price to book ratio is 17.33.
Transactions by insiders
Recent insider trading involved Krempa David, Chief Business Officer, that happened on Jun 12 ’25 when 16977.0 shares were sold. Chief Business Officer, Krempa David completed a deal on Jun 16 ’25 to sell 10223.0 shares. Meanwhile, Chief Business Officer Krempa David sold 6800.0 shares on Jun 13 ’25.
